Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its incretin drugs for diabetes and obesity were reaching a sales plateau.
Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its incretin drugs for diabetes and obesity were reaching a sales plateau.
